Phil Tennant
Known title: Chief Commercial OfficerCIK: 0002030874
Phil Tennant's purchase track record
Phil Tennant has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/29/2025 | PGEN | $21K | +22.6% | -10.5% | -4.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PGEN | ▲ Buy | Option Exercise | 79,166 | $127K | 8/25/2026 | View on chart |
| PGEN | ▼ Sell | Open Market | 79,166 | $594K | 8/25/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 5,208 | — | 8/23/2026 | View on chart |
| PGEN | ▼ Sell | Tax Withholding | 2,585 | $19K | 8/23/2026 | View on chart |
| PGEN | ▼ Sell | Open Market | 30,272 | $132K | 5/28/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 62,500 | — | 5/23/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 42,110 | — | 3/18/2026 | View on chart |
| PGEN | ▲ Buy | Open Market | 6,000 | $21K | 9/29/2025 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 66,441 | — | 5/16/2025 | View on chart |
| PGEN | ▼ Sell | Tax Withholding | 22,969 | $33K | 5/16/2025 | View on chart |
| PGEN | ▲ Buy | Grant | 25,000 | $0 | 1/29/2025 | View on chart |
| PGEN | ▼ Sell | Tax Withholding | 9,441 | $12K | 1/29/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Precigen mentioned in Zacks analyst blog
Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.
Precigen mentioned in Zacks analyst blog. Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.